瑞華新藥研發 第四屆抗癌新藥 ADI-PEG 20 研討會(2014.08.29)

The Fourth Symposium of ADI-PEG 20, A Novel Biologics For Cancer

瑞華藥業集團及關係企業Polaris Group 自2003年起參與抗癌新藥ADI-PEG 20的研發，已邁入第十二個年頭。

截至目前為止，全球已有超過800個癌症患者接受過ADI-PEG 20治療，公司在美、歐、台有多個臨床試驗在全球各地進行，其中包括攝護腺癌、胰腺癌、乳癌、子宮癌及非小細胞肺癌的第一期臨床試驗，血癌、淋巴癌及肺間皮癌的第二期臨床試驗，以及一個多國多中心的肝細胞癌三期臨床試驗，已陸續在美、台、英、義、韓、中各國各地收到70個癌症中心超過560名病人，預期在今年底會收滿所有病人，並在明年底在美、台、歐申請上市許可。

自2008年起，公司每隔兩年左右都會召開研討會，邀請國內外參與ADI-PEG 20的合作伙伴做專題報告，公布研發成果與醫、學、及業界先進交換心得，今年的研討會由於成果較為豐碩，將有9個專題報告，除臨床研發成果外，公司也將分享整體的策略規劃，以及未來數年的全球佈局。

日期：民國103年8月29日
時間：上午9:00～16:00
地點：台北君悅酒店 3F凱悅廳二區(台北市信義區松壽路二號)

議程 (Agenda)：

time	Topic	Speaker
09:00 – 09:10	Welcome	Bor-Wen Wu, Ph.D., CEO, Polaris Group & TDW Group
09:10 – 09:20	Introduction of ADI-PEG 20	Bor-Wen Wu, Ph.D., CEO, Polaris Group & TDW Group
09:20 – 09:55	Current Treatment of HCC and the Phase III ADI-PEG 20 Study	Ghassan Abou-Alfa, M.D., Attending Physician, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
09:55 – 10:30	Phase II Study of ADI-PEG 20 in Malignant Pleural Mesothelioma	Phase II Study of ADI-PEG 20 in Malignant Pleural Mesothelioma
10:30 – 10:45	Break
10:45 – 11:05	Phase II Study of ADI-PEG 20 in Acute Myeloid Leukemia	Li-Tzong Chen, M.D., Ph.D., Director, National Institute of Cancer Research, National Health Research Institute, Taiwan
11:05 – 11:25	Phase II Study of ADI-PEG 20 plus Transarterial Chemoembolization in HCC	Pei-Jer Chen, M.D., Ph.D., Professor, National Taiwan University, Taipei, Taiwan
11:25 – 11:45	ADI-PEG 20: Current Clinical Trial Results	John Bomalaski, M.D., Executive VP, Medical Affairs, Polaris Group
11:45 – 13:00	Lunch
13:05 – 13:25	ADI-PEG 20: Clinical Development Strategy	John Bomalaski, M.D., Executive VP, Medical Affairs, Polaris Group
13:25 – 14:00	Targeting Arginine Addiction of Prostate and Breast Cancer	Hsing-Jien Kung, Ph.D., President, National Health Research Institute, Taiwan
14:00 – 14:35	Current Treatment of Pancreatic Cancer and Phase IB Combination Study of ADI-PEG 20	Eileen O’Reilly, M.D., Attending Physician, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
14:35 – 14:50	Break
14:50 – 15:20	ADI-PEG 20: Registration Strategy	Shaw Chen, M.D., Ph.D. Executive VP, Regulatory Affairs, Polaris Group & TDW Group
15:20 – 15:50	What is Next for ADI-PEG 20: Corporate Strategy	Bor-Wen Wu, Ph.D., CEO, Polaris Group & TDW Group
15:50 – 16:00	Closing Summary